CARsgen Submits IND Applications for Innovative CAR-T Therapy

CARsgen Therapeutics Holdings Limited has taken a significant step in cancer treatment by submitting two Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for its allogeneic BCMA-targeted CAR-T cell therapy, known as CT0596. These applications aim to initiate Phase Ib/II clinical trials targeting relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL).

The CT0596 therapy leverages CARsgen’s proprietary THANK-u PlusTM platform. Designed with advanced gene editing techniques, it targets BCMA while knocking out genes such as NKG2A, TRAC, and B2M. This innovative approach aims to minimize the risk of graft-versus-host disease (GvHD) and host immune rejection, enhancing both efficacy and safety.

Encouraging Preliminary Data from Earlier Trials

Earlier investigator-initiated trials (IIT) conducted in China have already provided insights into CT0596’s clinical potential. Data presented at the 2025 American Society of Hematology (ASH) Annual Meeting highlighted a favorable safety profile alongside promising efficacy signals for patients with R/R MM. As of August 31, 2025, all eight patients infused with CT0596 were evaluable for efficacy, with a median follow-up of 4.14 months.

Among these patients, six achieved a partial response or better, including three who reached a complete response or stringent complete response (CR/sCR). Notably, all three had undergone full-dose lymphodepletion. Additionally, one patient recorded a very good partial response (VGPR), and two achieved partial responses (PR). The treatment was well-tolerated, with only four patients experiencing Grade 1 cytokine release syndrome (CRS) and no reports of Grade 2 or higher CRS, GvHD, or treatment-related deaths.

In a separate set of trials for patients with pPCL, two heavily pretreated individuals demonstrated dramatic improvements, achieving stringent complete responses after receiving CT0596.

Future Prospects and Development Goals

The recent IND submissions mark a critical phase in the registration clinical development of CT0596, signaling potential new options for patients suffering from R/R MM and pPCL. Future investigations may extend into other plasma cell malignancies and autoimmune diseases linked to plasma cells.

CARsgen Therapeutics is dedicated to addressing unmet medical needs through innovative CAR T-cell therapies. The company has established comprehensive capabilities in CAR T-cell research and development, covering everything from target discovery to commercial-scale production. Its mission is to become a global leader in biopharmaceuticals, providing cutting-edge cell therapies aimed at making cancer and other diseases more treatable.

As the landscape of cancer treatment evolves, CARsgen’s advancements represent a hopeful frontier in the fight against challenging hematologic malignancies. The outcomes of the ongoing trials for CT0596 will be closely monitored as the company aims to improve patient outcomes in this critical area of healthcare.